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AtherosclerosisAbstract Background: Insulin resistance (IR) is strongly associated with systemic inﬂammation.
Insulin resistance is known to be increased in patients with rheumatoid arthritis (RA) and has been
shown to be a risk factor for both clinical cardiovascular disease and subclinical atherosclerosis.
Aim of the work: To study the relationship between insulin resistance, disease activity and sub-
clinical atherosclerosis in RA patients.
Patients and methods: Forty RA patients and twenty age and sex matched healthy individuals as
controls were included. Patients with diabetes mellitus, obesity and hypertension were excluded.
Fasting plasma sugar and serum insulin were done, RA disease activity was assessed using the dis-
ease activity score (DAS28) and IR was evaluated by the homeostasis model assessment (HOMA2).
Carotid artery intima media thickness (IMT) was evaluated using ultrasound.
Results: RA patients had signiﬁcantly higher erythrocyte sedimentation rate (ESR), C-reactive
protein (CRP) positivity, fasting plasma sugar and fasting serum insulin, HOMA2-IR levels than
the controls. IR was present in 33 (82.5%) RA patients while it was present in only one (10%)
8 A.M. El Sayed et al.of the controls (p= 0.001). RA patients with IR had signiﬁcantly longer disease duration
(p= 0.003), higher disease activity (p= 0.000), greater carotid IMT (p= 0.000), and more carotid
plaques (p= 0.043) than those without insulin resistance. RA patients with increased IMT had sig-
niﬁcantly longer disease duration (p= 0.002), higher DAS28 score (p= 0.000) and higher
HOMA2-IR (p= 0.000) than those with normal IMT.
Conclusions: In RA patients, IR signiﬁcantly correlated with both disease activity and disease
duration. Our study pointed out a signiﬁcant association between IR and subclinical atherosclerosis
in RA.
 2013 Production and hosting by Elsevier B.V. on behalf of Egyptian Society for Joint Diseases and
Arthritis.Open access under CC BY-NC-ND license.1. Introduction
Rheumatoid arthritis (RA) is a systemic chronic inﬂammatory
disorder that affects mainly the joints and has been reported to
affect approximately 1% of the general population. Several
studies have documented the increased mortality and morbid-
ity rates in these patients [1–4], which could be due to under-
lying accelerated coronary artery and cerebrovascular
atherosclerosis (observed in a majority of the cases). Women
with RA are at twice the risk of developing myocardial infarc-
tion compared with women who do not have RA; however,
this increased risk is also seen in men [3,4]. Inﬂammation-
mediated vascular endothelial dysfunction has been shown to
lead to atherosclerosis, and has been found to be the major
contributing factor to increased cardiovascular morbidity
and mortality rates [5].
The pathogenesis of accelerated atherosclerosis in RA has
not yet been clearly deﬁned. Both traditional and nontradi-
tional risk factors contribute to atherogenesis in RA [5,6].
Among these risk factors is insulin resistance, which is
previously reported among patients with RA. Inﬂammatory
blockade improves pancreatic islet function and the proinﬂam-
matory cytokines associated with RA induce beta cell toxicity
and predispose to insulin resistance [7–9]. Also, the glucocorti-
coid therapy which is widely used for the treatment of RA have
also the potential to adversely affect beta cell function and
predispose to insulin resistance [10–12]. In addition, RA
patients experience a diabetes prevalence of 10–20% [13–15],
and diabetes predicts increased rates of cardiovascular events
in this disease [14,15].
It has been hypothesized that insulin resistance (IR) may
have a role in promoting atherosclerosis in RA [16]. Impaired
insulin sensitivity has been shown to be an independent cardio-
vascular risk factor in individuals with [17] and without [18]
diabetes. Despite this evidence, the association between IR
and atherosclerosis in RA remains under debate, even though
a previous study has suggested a relationship between IR and
accelerated atherogenesis in active RA [19].
The aim of the present study was to evaluate the relation-
ship between insulin resistance, disease activity and subclinical
atherosclerosis in RA patients.
2. Patients and methods
2.1. Clinical evaluation
The present cross sectional case control study was conducted
on sixty participants; forty RA patients who fulﬁlled the newAmerican College of Rheumatology/European League against
Rheumatism (ACR/EULAR) panel [20] and twenty healthy
age matched volunteers randomly selected as a control
group.
The patients were randomly recruited from the rheumatol-
ogy outpatient clinic and rheumatology in-patient Department
of Ain shams University Hospital; All subjects gave written in-
formed consent to participate, which was approved by the
Medical Ethics Committee. Patients with metabolic syndrome
or one of its related factors (diabetes mellitus, obesity, hyper-
tension, dyslipidemia) and smokers were excluded from the
study.
Patients were subjected to the following procedures: full
medical history; thorough clinical examination including gen-
eral, systemic (esp. blood pressure measurement and body
mass index calculation) and musculoskeletal examinations.
RA disease activity was assessed by the Disease Activity
Score28 (DAS28) [21], with low disease activity is deﬁned as
DAS28 6 3.2, moderate as 3.2 < DAS28 6 5.1, high as
DAS28 > 5.1 and remission DAS28 < 2.6 [22].2.2. Laboratory evaluation
Patients’ venous blood samples (8 mL each) were collected by
venipuncture, 5 mL was placed in EDTA for a complete blood
count (CBC) and for the determination of erythrocyte sedi-
mentation rate (ESR). 3 mL of the sample was centrifuged
immediately. The plasma was removed and stored at 2–8 C
until testing can be performed. Complete blood count
(CBC): [Coulter counter (T660)]. First hour Erythrocyte sedi-
mentation rate (ESR) was estimated by the Westergren meth-
od. Rheumatoid factor (RF) was measured by using biotic RA
factor latex agglutination slide technique for the qualitative
determination of RF in serum. Blood urea nitrogen (BUN),
serum creatinine, serum alanine and aspartate aminotransfer-
ase (AST and ALT) were measured. C-reactive protein
(CRP) was detected using a latex agglutination kit, where a va-
lue P6 mg/l. was considered positive according to the manu-
facturers’ instructions. Fasting plasma sugar and Fasting
serum insulin (ELISA method) were tested simultaneously.
The used reference ranges were: for adult fasting non dia-
betic, serum insulin of more than 9 lU/ml was considered as
high fasting serum insulin.
Insulin resistance (IR) which is the main outcome of the
metabolic syndrome was evaluated by the homeostasis model
assessment (HOMA) (calculator available from (www.
OCDEM.ox.ac.uk), which is based on fasting plasma glucose
and serum insulin concentrations [23]. The output of the
Figure 1 Correlation between HOMA IR and DAS28 in RA
patients.
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100% and an IR of 1 as normal. Therefore, values were con-
sidered abnormal when HOMA2-IR was >1 [24].
2.3. Radiological assessment
The patients were examined using Logiq – 500 MD (GE
Yokogawa Medical Co., Japan) medical scanner equipped
with a 6–9 MHz wideband linear array transducer at the Radi-
odiagnosis unit, Ain shams University Hospital. The examina-
tions were carried out by the same radiologist who scanned
common carotid, the carotid bulbs, the proximal internal
and external carotid arteries. All the patients had the intima –
media thickness (IMT) of their carotid artery measured. The
patients were placed in supine position with the chin extended,
turning the head away from the side being examined. The com-
mon carotid artery was scanned longitudinally, and the IMT
measurement was taken approximately 1 cm proximal to the
carotid bulb as the maximum distance between the intima –
lumen and adventitia – media interfaces in areas without
carotid plaque. IMT was determined as the average of six mea-
surements, three each from the left and right common carotid
arteries. Axial scanning was also performed searching for the
presence of any carotid plaques and their dimensions were
measured meticulously. A cut off value of 0.72 mm was taken
for IMT, patients who had IMT above this value were consid-
ered to have atherosclerosis [25].
The collected data were coded, tabulated, and statistically
analyzed on an IBM computer using Statistical Package for
Social Science (SPSS) version 17.0. Quantitative variables were
described as mean, standard deviation (SD) and range. Quali-
tative variables were described as number and percentage. The
unpaired t-test was used to compare two groups regarding
quantitative variables. The Chi-square test was used to com-
pare qualitative variables between groups. One way ANOVA
test was used to compare more than two groups as regardsTable 1 Comparison between RA patients group and control grou
Variable RA Patients group n= 40 Mean ± SD
Age (years) 48.28 ± 10.45
Sex
Male 6 (15%)
Female 34 (85%)
BMI (kg/m2) 23.16 ± 2.09
Hemoglobin (gm/dl) 10.79 ± 1.18
Platelets (·103/mm3) 292.70 ± 76.02
ESR (mm/1st hr) 71.08 ± 31.92
CRP
Positive 27 (67.5%)
Negative 13 (32.5%)
RF
Positive 28 (70%)
Negative 12 (30%)
Anti CCP
Positive 30 (75%)
Negative 10 (25%)
S. Insulin (uIU/ml) 13.96 ± 5.40
FBS (mg/dL) 103.77 ± 5.85
HOMA2 IR 1.86 ± 0.70
RA= rheumatoid arthritis; ESR= Erythrocyte sedimentation rate; CR
cyclic citrullinated peptide; FBS = fasting blood sugar; HOMA2 IR= hquantitative variables. Spearman correlation test was used to
rank different variables against each other positively or inver-
sely. Logistic regression analysis was used to discover the effect
of qualitative parameters in another parameter. P value 60.05
was considered statistically signiﬁcant, p> 0.05 was statisti-
cally insigniﬁcant and p 6 0.001 was considered highly statisti-
cally signiﬁcant.
3. Results
Forty RA patients were included in the study (34 females and 6
males). Their mean ± SD of age was 48.28 ± 10.45 years.
Twenty age and gender matched healthy volunteers (14 fe-
males and 6 males) were included as the control group. Theirp regarding the studied parameters.
Control group n= 20 Mean ± SD p-Value
43.65 ± 10.19 0.108
6 (30%) 0.171
14 (70%)
24.11 ± 1.54 0.920
12.23 ± 1.18 0.000
272.70 ± 44.41 0.282
12.40 ± 2.91 0.000
0 (0%) 0.000
20 (100%)
3 (15%) 0.000
17 (85%)
0 (0%) 0.000
20 (100%)
6.70 ± 1.42 0.000
93.65 ± 9.34 0.000
0.86 ± 0.18 0.000
P = C-reactive protein; RF = rheumatoid factor; Anti-CCP= anti
omeostasis model assessment for insulin resistance.
Figure 2 Correlation between HOMA IR and carotid intima
media thickness in RA patients.
Figure 3 Carotid Doppler ultrasound of a subject with normal
IMT.
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niﬁcant difference between the groups regarding gender, age or
their body mass index (BMI).
RA patients had signiﬁcantly higher ESR, CRP positivity,
RF positivity, anti-CCP positivity, fasting serum insulin, fast-
ing blood sugar and levels of HOMA-IR than the controls
(Table 1).
There were signiﬁcant positive correlations between
HOMA2-IR levels and disease duration (r= 0.516,Table 3 Comparison between RA patients with different disease ac
Disease activity
state (DAS 28)
Mild activity
2.6 < DAS 28 6 3.2
no = 3
Mo
3.2 <
no =
Mean ± SD Mea
HOMA-IR 2 0.800 ± 0.100 1.02
Carotid IMT (mm) 0.627 ± 0.055 0.75
HOMA2 IR= homeostasis model assessment for insulin resistance; IMT
Table 2 Comparison between RA patients with insulin resistance (H
regarding the studied parameters.
Variable HOMA2 IR 6 1 no = 7
Mean ± SD
Age (years) 41.86 ± 10.95
Disease duration (years) 6.14 ± 2.73
ESR (mm/1st hr) 21.29 ± 5.59
DAS-28 3.55 ± 0.46
Serum Insulin (lU/ml) 5.71 ± 0.95
Carotid IMT (mm) 0.69 ± 0.07
Plaques
Positive 0 (0.00%)
Negative 7 (100.00%)
Cumulative oral steroid dose (gm) 20.76 ± 8.22
Current oral daily steroid dose (mg) 7.5 ± 2.04
RA= rheumatoid arthritis; HOMA2 IR = homeostasis model assessm
DAS-28 = disease activity score.P= 0.001), ESR levels (r= 0.856, P= 0.000), disease activity
by DAS-28 (r= 0.969, P= 0.000) Fig. 1, and carotid intima
media thickness (r= 0.926, P= 0.000) Fig. 2. No signiﬁcant
correlation was found between HOMA2-IR levels with neither
the cumulative steroid dose(r= 0.193, P= 0.321) nor the cur-
rent daily dose (r= 0.213, P= 0.301).
RA patients with insulin resistance (HOMA2 IR > 1) were
found to have signiﬁcantly longer disease duration
(P= 0.003), higher disease activity (P= 0.000), higher caro-
tid intima thickness (P= 0.000) and in addition, presentedtivity states regarding HOMA2-IR and carotid IMT.
derate activity
DAS 28 6 5.1
9
Severe activity DAS
28 > 5.1 No = 28
One Way
ANOVA
n± SD Mean ± SD P
2 ± 0.282 2.236 ± 0.430 0.000
0 ± 0.036 0.884 ± 0.051 0.000
= intima media thickness; DAS-28 = disease activity score.
OMA2 IR > 1) and without insulin resistance (HOMA2 IR 6 1)
HOMA2 IR> 1 no = 33 Independent t-test
Mean ± SD p-Value
49.64 ± 9.98 0.073
12.30 ± 4.84 0.003
81.64 ± 24.05 0.000
6.19 ± 0.94 0.000
15.71 ± 4.15 0.000
0.87 ± 0.07 0.000
13 (39.40%) 0.043
20 (60.60%)
25.66 ± 10.99 0.246
6.76 ± 2.02 0.425
ent for insulin resistance; ESR= Erythrocyte sedimentation rate;
Table 4 Comparison of RA patients with an increased and normal mean carotid IMT.
Variable IMT< 0.72 mm n= 7 Mean ± SD IMT> 0.72 mm n= 33 Mean ± SD Independent t-test p-value
Age (years) 42.29 ± 10.94 49.55 ± 10.05 0.095
BMI (kg/m2) 23.15 ± 2.1 22.95 ± 2.21 0.827
Disease duration (years) 6.00 ± 3.65 12.33 ± 4.69 0.002
DAS-28 3.77 ± 0.81 6.14 ± 1.02 0.000
ESR (mm/1st hr) 30.57 ± 22.14 79.67 ± 26.73 0.000
S. Insulin (uIU/ml) 6.57 ± 1.90 15.55 ± 4.48 0.000
HOMA2 IR 0.89 ± 0.23 2.06 ± 0.59 0.000
RA= rheumatoid arthritis; IMT= intima media thickness; BMI = body mass index; DAS-28 = disease activity score; ESR = Erythrocyte
sedimentation rate; HOMA2 IR= homeostasis model assessment for insulin resistance.
Figure 4 Carotid Doppler ultrasound of a subject with increased
IMT.
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resistance (Table 2). No signiﬁcant difference emerged between
both groups either in cumulative steroid dose
(19.29 ± 8.79 gm vs. 25.97 ± 10.02 gm, p= 0.110) or current
daily dose (6.79 ± 1.89 mg vs. 5.91 ± 2.15 mg, p= 0.324).
We further divided the patients according to DAS28 into
patients with mild disease activity (2.6 < DAS 6 3.2), patients
with moderate disease activity (3.2 < DAS 6 5.1) and patients
with severe disease activity (DAS > 5.1). Patients with severe
disease activity were found to have greater carotid intima
thickness (p= 0.000) and higher insulin resistance than those
with mild or moderate disease activity (p= 0.000) (Table 3).
RA patients with increased carotid intima thickness
(IMT> 0.72 mm) Fig. 4 presented signiﬁcantly more disease
duration (P= 0.002), higher disease activity (P= 0.000) and
have more insulin resistance than those with IMT 6 0.72 mm
Fig. 3 (Table 4).
Logistic regression analysis showed that insulin resistance
by (HOMA2 IR > 1) is a good predictor for subclinical ath-
erosclerosis (IMT > 0.72 mm) in RA patients (OR, 163.4;
95% Cl, 2.9–9214.68; P= 0.0132).
4. Discussion
Although a high prevalence of the metabolic syndrome and its
related factors such as obesity, dyslipidemia or impairedglucose metabolism was found in RA patients, only few studies
have speciﬁcally studied IR in this disease [26].
In the present study, insulin resistance determined by
HOMA-IR was found to be signiﬁcantly higher in RA patient
group (1.86 ± 0.70) compared with age and sex matched con-
trol group (0.86 ± 0.18).
La Montagna et al. [24] found an increased prevalence of
insulin resistance by HOMA in RA compared to controls
(p< 0.001). Similarly, Lee et al. [27] in a Korean study on
52 RA patients and a similar number of age and sex matched
controls, concluded that in patients with RA, IR measured by
HOMA IR was more signiﬁcantly increased than that of
healthy controls. Also, Chung et al. [28] studied (through the
HOMA test) IR in 104 patients with RA and compared the re-
sults with those of 124 cases of systemic lupus erythematosus.
They proved that patients with RA have a higher HOMA
index than that of lupus patients.
In a more recent and broad study done by da Cunha et al.
[29] on 283 RA patients and 226 healthy controls, they found
that frequency of metabolic syndrome deﬁned according to
National Cholesterol Education Program (NCEP) criteria
was signiﬁcantly higher in RA patients than in controls.
The only study that contradicts this hypothesis of a rela-
tionship between IR and RA is provided by Garcia Diaz [30]
who found no differences in HOMA and QUICKI values be-
tween RA patients and controls (74 cases and controls).
In the current study, we documented a positive correlation
between HOMA-IR and both RA disease duration and disease
activity (by DAS 28), as well as markers of disease activity
(ESR, CRP, number of tender and swollen joints). This sug-
gests a role for chronic inﬂammation in the development of
insulin resistance.
These results agree with the results of a previous study that
recruited 94 patients with RA, in whom insulin resistance and
beta cell function were studied by HOMA. It concluded that
IR (HOMA-IR) was associated with markers for inﬂammation
and disease activity such as C reactive protein, erythrocyte sed-
imentation rate and DAS28 [31]. Similar results were obtained
by Dessein et al. [32] who found that in patients with RA with
NCEP-deﬁned central obesity, insulin resistance explains a de-
gree of the variability of CRP concentrations equivalent to
that of disease activity.
Lee et al. [27] concluded that disease duration and CRP
are independent predictive factors for HOMA IR in RA
patients. Also, a signiﬁcant correlation was found among
RA patients between HOMA2-IR and DAS28 in the study
by La Montagna et al. [24].
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the degree of disease activity, where patients with severe dis-
ease activity were found to have higher serum insulin and IR
than those with mild to moderate disease activity. This agrees
with the results published by shahin et al. [33] where they
found that RA patients with high disease activity were more
insulin resistant than patients with moderate disease activity
(p= 0.0001).
On the contrary, Sahebari et al. [34] found no association
between the DAS 28 and the presence of metabolic syndrome
components. This could be explained by the fact that all RA
patients included in our study had active disease with most
of them in severe activity, also IR (the main outcome of the
metabolic syndrome) was not measured in their study.
Conﬂicting results have been found regarding the relation-
ship between IR and subclinical atherosclerosis [18,35]. La
Montagna et al. [24] showed a signiﬁcant correlation between
HOMA2-IR and increased carotid intima media thickness
(IMT), both in simple linear regression and in stepwise multi-
ple regression. With the latter, IMT was independently related
to HOMA2-IR.
Similarly, our results indicated a signiﬁcant positive corre-
lation between HOMA2-IR and carotid IMT and RA patients
with insulin resistance (HOMA2-IR > 1) were found to have a
signiﬁcantly higher IMT than those without insulin resistance
(p= 0.000). In addition, the presence of carotid plaques was
signiﬁcantly higher among RA patients with insulin resistance
than those without (p= 0.043).
Epidemiological studies have used different cut-off values
for IMT in the general population [36–39]. In accordance with
previous reports, the subclinical atherosclerosis IMT cut-off
value detected was >0.72 mm. [38,39] and accordingly we
chose to subdivide the RA patients into two groups, those with
a mean IMT 6 and >0.72 mm, respectively.
In our study when we compared between RA patients with
increased IMT and those with normal IMT, our results as well
those obtained from La Montagna et al. [24] revealed a signif-
icant difference between the two groups regarding DAS28 and
HOMA-IR. Moreover we found a signiﬁcant difference
regarding the disease duration.
In conclusion, we have conﬁrmed a higher prevalence of IR
among RA patients and indicated a signiﬁcant association be-
tween IR and subclinical atherosclerosis. In our cohort of RA
patients, IR detected by HOMA-IR2 was positively related to
both disease activity by DAS28 and disease duration.
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